Building the next generation of global leaders in life science
We found, build and fund companies to translate exceptional science into transformational treatments for patients in areas of high unmet need.
Syncona domain expertise
Our deep expertise in four key modalities enables the rapid translation of scientific research into companies with the potential to be global leaders and the development of a diversified portfolio of 15-20 companies
Making a positive contribution
We are committed to managing our business in a sustainable way, investing responsibly, and supporting our portfolio companies in making positive contributions to society by developing treatments that will make a difference to the lives of patients and their families.
Latest videos
Introduction to Richard Francis, Chief Executive of Purespring Therapeutics
Introduction from Quell Therapeutics, CEO, Iain McGill
Quell: the science and the unmet medical need for patients
Syncona’s Martin Murphy and Freddie Dear: Quell Series A expansion
Introducing Resolution Therapeutics
Introduction to Purespring
Syncona FY20: Martin Murphy discusses FY20 results
Syncona FY20: Martin Murphy discusses the impact of COVID-19
Syncona FY20: Martin Murphy discusses the outlook for Syncona
Achilles doses first patient
Gene Therapy explained
Building Syncona’s Gene Therapy platform
An introduction to Gene Therapy
Quell Therapeutics and an emerging area of cell therapy
Found, Build and Fund
Founding Quell Therapeutics
Measuring the potential impact of a gene therapy for patients
Achilles Therapeutics and the advent of immunotherapy
Latest insights
An expert multi-disciplinary team, attracting world-class talent
We are differentiated by our people, who identify innovative technology and take a commercial approach to building businesses capable of delivering transformational treatments to patients.
Leadership key facts
members of the investment team
years of life science and investment expertise
investment team with PhDs